Malaysia Expands Support for Domestic Drug Production Under NIMP 2030
Malaysia is strengthening support for domestic pharmaceutical manufacturing under the New Industrial Master Plan (NIMP) 2030, with a focus on increasing the local production of essential and generic medicines. According to research firm BMI, the policy direction aims to reduce healthcare costs while strengthening supply resilience. The approach also reflects a broader effort by the Ministry of Health (MOH) to reshape procurement and prescribing practices to favour cost‑effective treatments and improve public confidence in generic medicines.
As reported by research firm BMI, a unit of Fitch Solutions, Malaysia plans to raise the share of domestically produced medical products through targeted policy measures. These measures are intended to support local manufacturing capacity while enabling the government to better manage medicine pricing and availability across the healthcare system.
Public Procurement to Favour Local Pharmaceutical Production
Central to the strategy is the MOH’s procurement approach for pharmaceutical products and critical medical devices. Under this framework, suppliers that invest in local manufacturing are expected to receive greater consideration in government purchasing decisions.
The policy is designed to expand domestic supply while giving the government stronger leverage when negotiating prices. By prioritising lower-cost generic medicines where appropriate, officials aim to improve affordability across public healthcare services.
Generic-First Prescribing Strategy Reduces Costs
Malaysia has already recorded significant savings through its focus on generic medicines. In January 2026, the MOH reported that more than RM900 million had been saved over two years by prioritising generic drug use across both public and private healthcare sectors.
This effort is anchored in a generic‑first prescribing approach. When a generic version of a medicine is available, it is treated as the preferred prescribing option, encouraging healthcare providers to select cost‑effective alternatives without compromising therapeutic equivalence.
The framework is also intended to influence prescribing habits among clinicians and strengthen public trust in generics. Under Malaysia’s National Generic Medicines Framework, a generic medicine is defined as a product that becomes interchangeable with the original drug once patent or exclusivity rights expire, allowing other manufacturers to produce equivalent treatments at a lower cost.
Implications for Malaysia’s Pharmaceutical Manufacturing Sector
The policy direction is expected to accelerate growth in the country’s generic medicine segment while reinforcing domestic manufacturing capabilities. This aligns with broader industrial policies that aim to strengthen advanced production ecosystems, similar to initiatives highlighted in Malaysia’s adoption of Industry 4.0 systems in manufacturing.
Malaysia’s wider economic strategy has also focused on technology investment and industrial expansion, including efforts to attract high-value sectors and strengthen local supply chains, as seen in recent growth in technology and digital infrastructure investment.
However, BMI notes that the government’s shift towards more affordable treatment options may intensify competition for innovative pharmaceutical companies seeking to expand in Malaysia. As procurement policies increasingly favour cost-effective generics and local production, drugmakers will likely face greater pressure to demonstrate value and competitiveness in the Malaysian healthcare market.
